NCT05106335 2023-08-16A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLCJiangsu HengRui Medicine Co., Ltd.Phase 3 Terminated1 enrolled